Continuing Education Activity

Acute colonic pseudo-obstruction (ACPO), or Ogilvie syndrome, is a distinct form of colonic dilatation without underlying mechanical or anatomic etiology. Dilatation of the bowel is classically confined to the cecum and ascending colon with a transition near the splenic flexure. It is most commonly encountered in older adults with multiple underlying comorbidities but may also develop in otherwise healthy patients after a traumatic injury or following a surgical operation. This activity illustrates the evaluation and treatment of Ogilvie syndrome and reviews the role of interprofessional team members in managing those with this condition.

Objectives:

• Identify the etiology of Ogilvie syndrome.
• Assess the presentation of Ogilvie syndrome.
• Determine how Ogilvie syndrome is diagnosed.
• Communicate how an optimally functioning interprofessional team would coordinate care to enhance outcomes for patients with Ogilvie syndrome.

Introduction

Acute colonic pseudo-obstruction (ACPO), or Ogilvie syndrome, is a distinct form of colonic dilatation without evidence of underlying mechanical or anatomic cause. Dilatation of the bowel is classically confined to the cecum and ascending colon with a transition near the splenic flexure. It is most commonly encountered in older adults with multiple underlying comorbidities but may also develop in otherwise healthy patients after a traumatic injury or following a surgical operation. It is important to remember that the diagnosis of ACPO is 1 of exclusion and that more common causes of functional or mechanical bowel dilatation must be investigated. Symptoms and signs of the disease usually manifest over 3 to 5 days but may also develop more acutely, sometimes within 48 hours. ACPO is considered complicated when the patient develops any evidence of bowel ischemia, peritonitis, or perforation; the risk of complication increases directly with increasing cecal diameter and duration of illness. Supportive care with close observation remains the primary treatment for patients with uncomplicated ACPO, although early pharmacologic intervention is increasingly encouraged. Invasive procedures or surgery are indicated for disease refractory to conservative therapy or for those with a more severe initial presentation. Many patients recover with appropriate intervention, although morbidity and mortality increase substantially in patients who develop complications at any time during management.[1][2][3][4][5]

Etiology

The development of acute colonic pseudo-obstruction is unpredictable, and there are no definite causes; however, many clinical conditions that place a patient at increased risk have been identified. Advanced age, comorbidities associated with electrolyte imbalance or polypharmacy, and poor underlying functional status or immobility are all strongly associated. Older adults who have been hospitalized, even for non-operative care, are at increased risk. In a frequently cited retrospective study of 400 patients with ACPO, non-operative trauma, severe infection, and admission for cardiovascular disease were each considered predisposing conditions in approximately 10% of cases. Although all surgical operations place a patient at some increased risk for ileus, major orthopedic and obstetric procedures are most associated with the development of ACPO.

There appears to be a relationship to cesarean operations for unclear reasons. It is important to remember that not all patients who develop ACPO are hospitalized. Elderly adults presenting to the emergency department or other acute care settings from long-term care facilities or nursing homes, those with an underlying progressive neurological disease, or with recent abdominal surgery are all at increased risk.

Epidemiology

The incidence of this disease is frequently cited as approximately 100 cases per 100,000 hospital admissions every year, although some underreporting is suspected. Prevalence appears to be slightly increased in males, but the reason for this is unknown. The average age at presentation is approximately 60 years. Almost all patients have multiple underlying co-morbidities, and those who are functionally dependent at baseline develop the disease with the highest frequency. Surgical patients are most likely diagnosed on postoperative days 3 to 5.

Pathophysiology

While multiple risk factors for the development of ACPO have been established, a specific underlying mechanism has yet to be identified. Almost all investigators agree that there is impairment of the colonic motor system, with dysfunction or imbalance of the autonomic nervous system being the most likely cause. There is suspected to be reduced activity of stimulatory neurotransmitters, chiefly acetylcholine, relative to the inhibitory neurotransmitters, nitrous oxide, and vasoactive intestinal peptide. Independent dysfunction of the enteric nervous system, intrinsic enteric reflex arcs, and pacemaker activity contribute, but to what degree is unknown. Interestingly, in ACPO, pathologic distension of the colon usually ends at, or just proximal to, the splenic flexure, which is also where autonomic parasympathetic efferent innervation transitions from the Vagus nerve to the sacral, S2-S4, nerve roots.

As the cecum and ascending colon dilate and the luminal diameter increases, wall tension in the colonic mucosa increases proportionately. This increased wall tension leads to colonic ischemia, fluid and bacterial translocation, and colonic perforation. Colonic dilation's duration and absolute diameter influence the risk of bowel ischemia or perforation. Very few cases of perforation have been reported when the cecal diameter is less than 12 cm. However, there is evidence of a direct correlation between an increasing diameter of more than 12 cm and the risk of complications. Duration of ACPO appears to be the greatest factor for perforation or ischemia, with dilation lasting more than 5 or 6 days, conferring the highest risk and having a direct impact on mortality.[6][7][8][9]

History and Physical

Patients with acute colonic pseudo-obstruction present with gradually worsening abdominal distension and some degree of abdominal discomfort. Nausea and vomiting are usually present to some degree. Although bowel obstruction is classically taught to be associated with constipation and obstipation, a significant number of patients with ACPO continue to have some degree of bowel function, and diarrhea is possible due to the hypersecretion of water. It is important to remember that the majority of these patients have severe underlying co-morbidities or concurrent exacerbations of chronic disease, which may make the history unreliable.

The examination invariably shows some degree of abdominal distention. The abdomen is tympanic, and auscultation should reveal the presence of classically high-pitched bowel sounds. Some degree of abdominal tenderness is expected on the exam. Fever and any severe abdominal tenderness, with or without signs of peritonitis, are ominous findings suggestive of ischemia and perforation. Signs of peritonitis with abnormal vital signs should be concerning for sepsis.

Evaluation

Acute colonic pseudo-obstruction is an uncommon cause of bowel obstruction and is generally considered a diagnosis of exclusion. A thorough assessment, including contrast imaging, is necessary before the diagnosis of ACPO can be definitively made. Furthermore, the evaluation must assess for potentially reversible causes of ACPO and attempt to determine if any complications, such as ischemia or perforation, are present or imminent. 

Laboratory tests, although non-specific to the diagnosis, complete a thorough evaluation. If not associated with underlying disease, leukocytosis, elevated CRP, or lactate are concerning for bowel ischemia. Liver function tests, lipase, and human chorionic gonadotropin (HCG) should be obtained to help rule out other causes of acute abdominal pain. Electrolyte abnormalities, including magnesium and calcium, are common and have been reported to be present in up to two-thirds of post-operative patients. Thyroid function should be evaluated if a recent test is not available. Patients with diarrhea should be evaluated for Clostridium difficile toxin. Consider blood cultures in patients who appear septic.

Appropriate imaging is essential to the diagnosis and management of ACPO. Plain radiography, consisting of upright and supine abdominal films, is commonly performed but is limited in utility. Expected findings include varying degrees of colonic dilatation, normal haustral markings, and lack of signs of mechanical obstruction such as volvulus. Free air on acute abdominal series increases concern for perforation but does not rule perforation out. Perhaps the most important use of plain radiography is to measure the degree of initial colonic dilatation and for serial imaging during observation after diagnosis. CT scan with oral and intravenous (IV) contrast is the preferred modality for diagnosis. Rectal contrast is helpful but has been associated with iatrogenic perforation. Gastrografin or other water-soluble enteral contrast should be used. CT rules out anatomic or mechanical bowel obstruction as well as evaluates for more obscure causes of dilatation, such as retroperitoneal hematoma or abdominal abscess. CT scans can also show signs of ischemia, such as mucosal wall thickening, submucosal edema, or gas. Classically, ACPO on CT scan shows isolated dilatation of the cecum and ascending colon with a gradual transition zone or "cut off" at the splenic flexure. Suppose a CT scan is unavailable, and peritonitis is not appreciated during the examination. In that case, a contrast enema study can be performed, with a reported sensitivity of up to 96% in diagnosing ACPO. Lastly, diagnostic colonoscopy should be avoided in all patients with suspected ACPO, as gas insufflation is associated with an increased risk of perforation.

Treatment / Management

The primary goal of treatment is urgent bowel decompression. Treatment options for ACPO include conservative therapy with observation, direct pharmacologic interventions, and endoscopic therapies. Surgical or open-operative interventions are reserved for those failing endoscopic procedures or for patients who develop ischemia or perforation. The recommendations discussed in this topic are consistent with the American Society of Colon and Rectal Surgeons 2016 guidelines.

Patients diagnosed with uncomplicated ACPO should be admitted to the hospital to a unit where they can be carefully monitored. Initial management includes nothing by mouth (NPO) status and placement of a nasal gastric tube to aid in decompression. Patients should be carefully resuscitated with fluid as indicated. Electrolyte abnormalities and any other underlying disease exacerbations should be aggressively corrected. Medications that impact colonic motility, such as opiates and anticholinergics, should be discontinued as soon as possible, and it is also recommended that laxative medications be stopped. Patients should attempt to ambulate as frequently as clinically tolerated and, while in bed, should be encouraged to lie prone or in a knee-to-chest position with frequent turns to promote passage of flatus. Frequent repeat abdominal examinations are required. Laboratory tests, especially complete blood count (CBC) and electrolytes should be collected at least daily. A daily abdominal plain film should be obtained to monitor cecal dilatation. If there are no signs of complicated disease development and the cecal diameter remains less than 12 cm, this conservative approach should be continued for 72 hours and has a success rate of up to 90%.

Pharmacologic therapy should be initiated for patients who do not improve within 72 hours, have a duration of ACPO greater than 4 days, or develop a cecal diameter of greater than 12 cm. Neostigmine, a short-acting acetylcholinesterase inhibitor, is the drug of choice for treatment of ACPO. Evidence and popularity for its use in uncomplicated diseases are quickly increasing. Disease resolution is clinically defined as the passage of flatus or stool or decreasing cecal diameter. The medication is usually administered as a 2-mg, slow IV push over 2 to 5 minutes. Contraindications and adverse effects should be reviewed before use. Common adverse effects include abdominal discomfort, salivation, and vomiting, usually benign and transient. Patients should be closely monitored for more severe complications such as bradycardia and bronchorrhea. It is recommended that patients be on a continuous cardiac monitor during administration and for 30 additional minutes after administration. Atropine for symptomatic bradycardia should be available per ACLS guidelines. Glycopyrrolate can be used to treat respiratory secretions. A clinical response is typically seen within 2 to 30 minutes of administration. The average efficacy after 1 dose of neostigmine in randomized controlled trials is approximately 90%, with most non-responders having a disease resolution after a second 2-mg dose, which can be given 90 minutes to 3 hours after the first. A 24-hour neostigmine drip regimen has also been evaluated with a reported success rate of 85%, and fewer reported adverse effects. After an initial response to neostigmine, patients should continue to be monitored as approximately 30% are at risk of recurrence of cecal dilatation. There is evidence that oral administration of polyethylene glycol immediately after neostigmine response prevents this.

Patients who have contraindications to or fail pharmacologic therapy should be evaluated for endoscopic decompression. The procedure is considered technically difficult, and success rates are directly related to operator experience. Decompression is attempted through colonoscopy without gas insufflation or bowel preparation. After the dilated bowel has been evaluated and suction has removed air, a colonic decompression tube is usually placed as close to the cecum as possible via the endoscope. The decompression tube is then left to drainage externally with intermittent flushes. There is an approximately 3% risk of iatrogenic perforation during this procedure, and reoccurrence is still possible, although the placement of a decompression tube significantly reduces this event.

Traditional operative management is necessary when the interventions above are unsuccessful or when there is the development of bowel ischemia or perforation. A cecostomy decompression procedure can be attempted if a perforation is absent. If severe ischemia is found on endoscopy or perforation occurs, some degree of open resection is indicated with likely Hartmann procedure. Mortality rates increase substantially in ACPO when operative management is needed, regardless of whether perforation or non-viable bowel is present, and all attempts should be made to manage this disease more conservatively.[10][11][12]

Differential Diagnosis

The differential diagnosis of ACPO includes:

• Volvulus (cecal, sigmoid)
• Mesenteric ischemia
• Toxic megacolon
• Incarcerated hernia
• Intussusception
• Stricture
• Malignancy   
• Adynamic ileus 
• Constipation or stool impaction

Prognosis

The expected prognosis is confounded by the association of multiple co-morbidities in the usual patient population, as well as the underlying disease contributing to the development of ACPO. In general, the expected mortality after diagnosis of uncomplicated ACPO is approximately 15%. Complicated ACPO occurs in 3% to 15% of patients, which is associated with a much worse prognosis with average mortality rates between 30% and 40%. Factors associated with the development of complications include cecal diameter and duration of illness. In 1 study, no patients with a cecal diameter of less than 12 cm developed complicated disease, but 23% of patients with a cecal diameter of 14 cm did. Duration of dilation appears to have the most direct association with complicated disease and becomes concerning after 5 days, with a reported 5-fold increase in mortality rate after 7 days of unresolved disease. In patients who are actively treated, operative management has the highest mortality rate, which is likely due to operative therapy being reserved for those with complications or prolonged disease course; even without bowel ischemia, postoperative mortality rates are 26%. As can be seen, patient prognosis and survival depend on recognition, diagnosis, and timely colonic decompression.

Enhancing Healthcare Team Outcomes

Ogilvie syndrome can occur due to many causes and is best managed by an interprofessional team that includes a surgeon, radiologist, internist, nurse practitioner, and gastroenterologist. The primary goal of treatment is urgent bowel decompression. Treatment options for ACPO include conservative therapy with observation, direct pharmacologic interventions, and endoscopic therapies. Surgical or open-operative interventions are reserved for those failing endoscopic procedures or for patients who develop ischemia or perforation. The recommendations discussed in this topic are consistent with the American Society of Colon and Rectal Surgeons 2016 guidelines.

The expected prognosis is confounded by the association of multiple co-morbidities in the usual patient population, as well as the underlying disease contributing to the development of ACPO. In general, the expected mortality after diagnosis of uncomplicated ACPO is approximately 15%. Complicated ACPO occurs in 3% to 15% of patients, which is associated with a much worse prognosis with average mortality rates between 30% and 40%.[13]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Garbuzenko DV, Belov DV, Arefyev NO. A rare complication of cardiac surgery: Ogilvie syndrome. J Postgrad Med. 2019 Jan-Mar;65(1):56-57. [PMC free article: PMC6380123] [PubMed: 30693875]

2.

Song EM, Kim JW, Lee SH, Chang K, Hwang SW, Park SH, Yang DH, Jung KW, Ye BD, Byeon JS, Yang SK, Lee HJ, Yu CS, Kim CW, Park SH, Kim J, Myung SJ. Colonic Pseudo-obstruction With Transition Zone: A Peculiar Eastern Severe Dysmotility. J Neurogastroenterol Motil. 2019 Jan 31;25(1):137-147. [PMC free article: PMC6326194] [PubMed: 30646485]

3.

Ozawa T, Ishihara S, Okada Y, Ohno K, Yagi T, Fukushima Y, Shimada R, Hayama T, Tsuchiya T, Nozawa K, Matsuda K, Matsuoka R, Mori I, Fukuzawa R, Takiyama A, Takao Y, Shimizu N, Kikuchi K, Hashiguchi Y. Laparoscopic subtotal colectomy for a patient with chronic idiopathic colonic pseudo-obstruction: Report of a case. Asian J Endosc Surg. 2019 Oct;12(4):469-472. [PubMed: 30618177]

4.

Maxim R, Pleşa A, Stanciu C, Girleanu I, Moraru E, Trifan A. Helicobacter pylori prevalence and risk factors among children with celiac disease. Turk J Gastroenterol. 2019 Mar;30(3):284-289. [PMC free article: PMC6428505] [PubMed: 30460898]

5.

Shahait AD, Mostafa G. Ogilvie's Syndrome or Colonic Pseudo-Obstruction. Am Surg. 2018 Jan 01;84(1):e38-e39. [PubMed: 30454296]

6.

Deane AM, Chapman MJ, Reintam Blaser A, McClave SA, Emmanuel A. Pathophysiology and Treatment of Gastrointestinal Motility Disorders in the Acutely Ill. Nutr Clin Pract. 2019 Feb;34(1):23-36. [PubMed: 30294835]

7.

de Jonge CS, Smout AJPM, Nederveen AJ, Stoker J. Evaluation of gastrointestinal motility with MRI: Advances, challenges and opportunities. Neurogastroenterol Motil. 2018 Jan;30(1) [PubMed: 29265641]

8.

Wells CI, O'Grady G, Bissett IP. Acute colonic pseudo-obstruction: A systematic review of aetiology and mechanisms. World J Gastroenterol. 2017 Aug 14;23(30):5634-5644. [PMC free article: PMC5558126] [PubMed: 28852322]

9.

Vazquez-Sandoval A, Ghamande S, Surani S. Critically ill patients and gut motility: Are we addressing it? World J Gastrointest Pharmacol Ther. 2017 Aug 06;8(3):174-179. [PMC free article: PMC5547375] [PubMed: 28828195]

10.

Costa G, Ruscelli P, Balducci G, Buccoliero F, Lorenzon L, Frezza B, Chirletti P, Stagnitti F, Miniello S, Stella F. Clinical strategies for the management of intestinal obstruction and pseudo-obstruction. A Delphi Consensus study of SICUT (Società Italiana di Chirurgia d'Urgenza e del Trauma). Ann Ital Chir. 2016;87:105-17. [PubMed: 27179226]

11.

ASGE Standards of Practice Committee. Harrison ME, Anderson MA, Appalaneni V, Banerjee S, Ben-Menachem T, Cash BD, Fanelli RD, Fisher L, Fukami N, Gan SI, Ikenberry SO, Jain R, Khan K, Krinsky ML, Maple JT, Shen B, Van Guilder T, Baron TH, Dominitz JA. The role of endoscopy in the management of patients with known and suspected colonic obstruction and pseudo-obstruction. Gastrointest Endosc. 2010 Apr;71(4):669-79. [PubMed: 20363408]

12.

Haack H. [Intestinal pseudo-obstruction]. Ther Umsch. 2007 Apr;64(4):217-20. [PubMed: 17663208]

13.

Haj M, Haj M, Rockey DC. Ogilvie's syndrome: management and outcomes. Medicine (Baltimore). 2018 Jul;97(27):e11187. [PMC free article: PMC6076157] [PubMed: 29979381]

Disclosure: Stuart Conner declares no relevant financial relationships with ineligible companies.

Disclosure: Ali Nassereddin declares no relevant financial relationships with ineligible companies.

Disclosure: Christopher Mitchell declares no relevant financial relationships with ineligible companies.